Globe NewswireOther News

Helius Medical Technologies, Inc. Announces PoNS® Is Now Available on the Veterans Affairs (VA) Federal Supply Schedule (FSS) and General Services Administration (GSA) Advantage Contracts

86

— Approval provides U.S. veterans and other U.S. government agency employees who suffer gait and balance impairment due to multiple sclerosis (MS) access to the only portable neurostimulation therapy with the potential to generate neuroplasticity —

NEWTOWN, Pa., May 20, 2024 – Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced the Company’s Portable Neuromodulation Stimulator (PoNS®) device has been approved for inclusion on Lovell Government Services’ (“Lovell”) Veterans Affairs (VA) Federal Supply Schedule (FSS) and General Services Administration (GSA) Advantage contracts.

The contract award number #V797D-50450 enables the VA and other Federal entities to purchase PoNS at pre-approved pricing via the VA’s FSS Medical Equipment and Surgical (Med/Surg) Contract at VA National Acquisition Center MedSurg Catalog and via the GSA Advantage online catalog at GSA Advantage. The PoNS system, Item # S1-001-02, is priced at $23,843.72 and the PoNS mouthpiece, Item # M1-001 is priced at $7,344.97. PoNS is indicated in the U.S. for use as a short-term treatment of gait deficit in adults with mild-to-moderate symptoms from MS when used in conjunction with physical therapy.

The VA estimates that between 55,000 and 70,000 veterans in the U.S. live with MS.

“We’re proud that PoNS is now available to veterans and Federal employees under the VA Healthcare System. PoNS is the only portable and readily accessible therapy that may lead to neuroplasticity, or the brain’s ability to modify, change, or adapt in response to modulation of brain activity, making PoNS Therapy® a game changer for those affected by MS. The inclusion of PoNS on the FSS Med/Surg and GSA Advantage marketplace means that those who suffer gait or balance impairment will have quicker, more efficient access to this groundbreaking therapy. We are grateful for our partnership with Lovell and the opportunity to not only establish Helius as a preferred provider but, more importantly, get PoNS into the hands of the veterans and Federal employees who need it the most,” said Dane Andreeff, President and Chief Executive Officer of Helius.